Following approval of hepatitis C virus protease inhibitors Incivek and Victrelis, companies are partnering to devise all-oral combination antiviral regimens without interferon α. But the virus is a long way from vanquished. Ken Garber investigates.
Access options
Subscribe to Journal
Get full journal access for 1 year
$250.00
only $20.83 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
from$8.99
All prices are NET prices.
References
- 1.
Kwong, A.D. et al. Nat. Biotechnol. 29, 993–1003. (2011).
- 2.
Lok, A. et al. J. Hepatol. 54, Suppl. 1, S536, abstract 1356 (2011).
- 3.
Fried, M. et al. AASLD annual meeting abstract LB-5 (2011).
- 4.
Garber, K. Nat. Biotechnol. 25, 1379–1381 (2007).
- 5.
Gao, M. et al. Nature 465, 96–100 (2010).
- 6.
Tellinghuisen, T.L. et al. Nature 435, 374–379 (2005).
- 7.
Chayama, K. et al. AASLD annual meeting abstract LB-4 (2011).
- 8.
Ge, D. et al. Nature 461, 399–401 (2009).
- 9.
Thomas, D.L. et al. Nature 461, 798–801 (2009).
- 10.
Murray, C.L. & Rice, C.M. Nature 465, 42–44 (2010).
Author information
Affiliations
Ann Arbor, Michigan
- Ken Garber
Authors
Search for Ken Garber in:
Rights and permissions
To obtain permission to re-use content from this article visit RightsLink.
About this article
Further reading
-
FDA approvals usher in the post-interferon era in HCV
Nature Biotechnology (2014)
-
Gilead's $11 billion HCV bet
Nature Biotechnology (2012)
-
New Pharmacotherapy for Hepatitis C
Clinical Pharmacology & Therapeutics (2012)
